News
Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...
Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent ...
What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...
A client in Ireland acquired an aseptic operations facility with plans to expand into GMP microbiology laboratory services, despite having previously outsourced all microbiology work and lacking ...
<p>On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, ...
A major biopharmaceutical company faced equity and operational challenges from relying on temporary employees in long-term roles. These workers lacked full-time status and received limited, costly ...
More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.
Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an ...
Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...
By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL John Oyler Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with ...
<p data-pm-slice="1 1 []">Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity ...
<p>Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results